Could Flozins Be the Statins for Risk-Based Primary Prevention of Heart Failure?

JAMA Cardiol. 2021 Jul 1;6(7):741-742. doi: 10.1001/jamacardio.2021.1133.

Authors

Priya M Freaney^{1

2}, Donald M Lloyd-Jones^{1

2}, Sadiya S Khan^{1

2}

Affiliations

¹ Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

PMID: 34009240
DOI: 10.1001/jamacardio.2021.1133

No abstract available

MeSH terms

Coronary Disease / prevention & control
Heart Failure / etiology
Heart Failure / prevention & control*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Primary Prevention / methods*
Risk Factors
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Sodium-Glucose Transporter 2 Inhibitors